Aims: The AleCardio trial aimed to characterize the efficacy and safety of peroxisome proliferator-activated receptor-αγ agonist aleglitazar in patients with type 2 diabetes mellitus and acute coronary syndrome. The trial terminated early because of futility and safety signals. We evaluated whether the safety signals could be attributed to increased exposure to aleglitazar.
Conclusions: Concomitant use of clopidogrel was identified as a covariate that explained interindividual variability in exposure to aleglitazar. Patients using clopidogrel showed an additional lowering of HbA1c, at the expense of an additional decrease in haemoglobin, and an increase in serum creatinine and adiponectin.
Clopidogrel is a moderate inhibitor of CYP2C8. Because aleglitazar is metabolized by CYP2C8, a pharmacokinetic interaction could explain differences in exposure and response to aleglitazar. has been shown to improve glycaemic variables and lipid profile in patients with type 2 diabetes mellitus. 1, 2 However, PPAR-γ activation may lead to sodium and fluid retention, particularly in patients with type 2 diabetes who are prone to sodium and fluid retention. 3 The AleCardio trial was designed to determine whether aleglitazar compared with placebo reduces cardiovascular morbidity and mortality among patients with type 2 diabetes mellitus and a recent acute coronary syndrome (ACS). 4 The trial was terminated early because of futility for efficacy and increased rates of congestive heart failure, bone fractures and gastrointestinal haemorrhage associated with aleglitazar. 5 The increased rate of congestive heart failure is probably a result of sodium and fluid retention following PPAR-γ activation.
Patients assigned to aleglitazar received a fixed dose of 150 μg daily. It is unknown whether increased exposure to aleglitazar contributed to the safety findings in the trial. The aim of the current study was therefore to characterize the interindividual variation in exposure to aleglitazar, to determine the factors associated with aleglitazar exposure, and to assess the association between aleglitazar exposure and safety and efficacy measures.
| MATERIALS AND METHODS

| Study design and patient population
The design of the AleCardio trial (Clinicaltrials.gov trial registration number: NCT01042769; registration date: January 6, 2010) has been reported previously. 4, 5 The study protocol of the AleCardio trial was approved by the appropriate national and institutional regulatory and ethical boards.
Briefly, qualifying patients were hospitalized for ACS (defined as unstable angina or acute myocardial infarction) with established or newly diagnosed type 2 diabetes mellitus. Exclusion criteria included symptomatic heart failure or hospitalization with a primary diagnosis of heart failure within the previous year, severe peripheral edema, an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m 2 , or treatment with another PPAR agonist. A total of 7226 patients at 720 sites in 26 countries were enrolled between February 2010 and May 2012. Between hospital discharge after ACS and 12 weeks thereafter, patients were randomized in a double-blind, 1:1 ratio to receive aleglitazar (150 μg per day) or matching placebo on top of standard therapy. Patients were asked to take study medication at the same time of the day throughout the study, but a specific time of day or relation to meals was not specified. The primary efficacy endpoint was time to cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Principal safety endpoints were hospitalization caused by heart failure and changes in renal function. Efficacy measures and hospitalization for heart failure were adjudicated by a blinded clinical events committee. Other adverse events of special interest were edema, bone fractures, hypoglycaemia and malignancies. Upon the recommendation of the data and safety monitoring board, the trial was terminated in July 2013 with a median follow-up of 2 years because of futility for efficacy and increased rates of safety endpoints with aleglitazar.
In a pharmacokinetic substudy, plasma samples were collected in 515 of 3616 patients treated with aleglitazar. In this substudy, patients were divided into two groups with different pharmacokinetic sampling schemes. In the first group (n = 117), a total of four samples were collected at predose and between 30-120, 121-180 and 181-240 minutes after administration of aleglitazar at a single study visit. In the second group (n = 398), again a total of four samples were collected; however, in this group a sample was collected predose and postdose at two consecutive study visits. For the purpose of analysis, data of both groups were pooled. Actual dosing times and sampling times were recorded. Pharmacodynamic samples were collected for all patients throughout the AleCardio trial at multiple study visits.
| Population pharmacokinetic analysis
A stepwise approach was used to develop the pharmacokinetic model. Different structural models with linear absorption and elimination processes were explored, including one-and two-compartment models. Parameter estimates were obtained using first-order conditional estimation with interaction. Interindividual variability (IIV) was incorporated in the model, assuming a log-normal distribution of the random effects on the model parameters. Also, covariance between random effects was formally tested. Additive, proportional and combination residual variability models were tested. Covariate screening was performed for the following covariates: eGFR at baseline, body 
| Clinical outcomes
The effects of covariates that influenced exposure were further explored on hard outcomes that caused the early termination of the AleCardio trial. The safety measures-hospitalization for heart failure, gastrointestinal haemorrhage and bone fractures-were evaluated using Cox proportional hazard models. All patients were stratified based on the approach described under surrogate outcomes. Treatment, covariate stratum and the interaction between treatment and covariate stratum were included in the models. Hazard ratios including 95% confidence intervals were estimated for all patients and for the stratified patient populations.
All data preparation and presentation was performed using R ver- 
| RESULTS
| Population pharmacokinetic analysis
In total, 1855 plasma samples collected from 514 patients in the aleglitazar group were used for the pharmacokinetic analysis. Of these, 94 samples were excluded based on concentration below the lower limit of quantification (n = 59), insufficient volume to assay the sample (n = 13), missing dosing information (n = 23) and erroneous randomization to placebo instead of aleglitazar (n = 1). This resulted in the inclusion of 1761 samples from 514 patients, with one to four samples per patient. Most plasma samples were drawn 0-4 hours postdose (n = 1005) and most of the predose samples (n = 693) were drawn at least 20 hours after the preceding dose. The demographics of the patients included in the population pharmacokinetic analysis are presented in Table 1 . Figure S1 and parameter estimates are tabulated in Table 2 .
The goodness-of-fit plots indicated that the high concentrations appear to be slightly underestimated. However, population parameter estimates were estimated with high precision as indicated by their low RSE, ranging from 4.2%-19.0%. The CV of CL/F was 57.1% with low shrinkage (6%). The CV for the IIV on V2/F was high (587%) with accompanying high shrinkage (37%). As inclusion of IIV on the V2/F improved the individual fit of the data in terms of MOFV, residuals and goodness-of-fit plots, it was decided to include this random effect The baseline characteristics are displayed for patients included in the population pharmacokinetic analysis and in the pharmacodynamic analysis. All variables are displayed as mean (SD), only sex, smoking status and race are displayed as number of patients (% of patients). 
| Pharmacodynamic analysis
| Surrogate outcomes
The absolute change in HbA1c, serum creatinine, haemoglobin, body weight, adiponectin and triglycerides over time, stratified by treatment and clopidogrel use, are displayed in Figure 2 . The effect of aleglitazar compared with placebo on HbA1c, haemoglobin, serum creatinine and adiponectin was modified by concomitant clopidogrel use (P for interaction 0.007, 0.002, <0.001 and <0.001, respectively; Table 3 ). The direction of the interaction was such that aleglitazar compared with placebo caused a larger reduction in HbA1c and haemoglobin and a larger increase in serum creatinine and adiponectin in patients who were concomitantly using clopidogrel versus patients who were not. The effect of aleglitazar compared with placebo on body weight and triglycerides was not modified by concomitant clopidogrel use (P for interaction 0.434 and 0.318, respectively).
| Clinical outcomes
The influence of concomitant administration of clopidogrel with aleglitazar on clinical outcomes is displayed in Figure 3 . The effect of aleglitazar compared with placebo on the risks of hospitalization for heart failure was modified by clopidogrel use (P for interaction 0.01).
Specifically, aleglitazar caused an increased risk of hospitalization for heart failure (HR: 1.21, 95% CI: 1.04-1.40) in patients with concomitant clopidogrel use. Conversely, aleglitazar showed a trend for a decreased risk of hospitalization for heart failure (HR: 0.78, 95% CI: 0.57-1.06) among patients without using clopidogrel. No effect modification by clopidogrel was observed for bone fractures or gastrointestinal haemorrhage (Figure 3 ).
| DISCUSSION
A large variation between individuals was observed in the plasma concentrations of aleglitazar in the AleCardio trial. We found that the plasma concentration-time profile of aleglitazar was best described using a two-compartment model with first-order absorption, firstorder elimination and allometric scaling. Using this model, we showed that part of the observed IIV could be attributed to a reduced The pharmacodynamic analysis revealed that patients receiving concomitant clopidogrel showed larger reductions in HbA1c and haemoglobin and a larger increase in serum creatinine and adiponectin compared with patients who did not use clopidogrel.
In this study we found that the observed variability between individuals in the plasma concentration-time profile of aleglitazar in the AleCardio trial population, after administration of the therapeutic 150 μg/day aleglitazar dose, covered the complete dose range of 20-900 μg/day observed in a prior study of patients with type 2 diabetes mellitus. 7 To better characterize the variability in the pharmacokinetics of aleglitazar in the AleCardio trial population, a population pharmacokinetic analysis was conducted. The developed twocompartment model with first-order absorption and first-order elimination described the data best, which is in line with a previously reported population pharmacokinetic analysis based on data from the SYNCHRONY trial. 8 Inclusion of a food effect on the absorption rate constant and an effect of concomitant administration of clopidogrel on the apparent clearance improved the overall model fit and explained part of the IIV.
In the AleCardio population, t max ranged from 0.2 to 3.9 hours, which appears to be faster than previously reported in patients with type 2 diabetes mellitus (ranging from 2.0 to 8.0 hours). 7 The population pharmacokinetic model identified a food effect on the absorption rate constant that could partly explain the fast absorption.
Under fasting conditions, the absorption rate constant increased by 23.9%. The absorption phase of aleglitazar was estimated with high precision (RSEs were 15.5% for KA and 6% for the food effect). Nonetheless, to our knowledge, dedicated clinical studies on the food effects of aleglitazar have not been published and therefore our results, obtained from a post hoc analysis, should be carefully interpreted. Nevertheless, they are in line with a mass-balance study that reported fast absorption under fasting conditions (t max ranging from 0.47 to 1.0 hours). 9 Alternatively, the fast absorption may be caused by a formulation effect because the mass-balance study used an oral aleglitazar solution. 9 Co-medication that could potentially influence the pharmacokinetics of aleglitazar was investigated as a covariate in the population pharmacokinetic model. Patients using both aleglitazar and clopidogrel showed a 16.4% lower apparent clearance, which results in a higher exposure to aleglitazar compared with patients solely treated with aleglitazar (AUC 0-24 of 174.7, SD 112.9 ng h/mL and 142.2, SD 92.6 ng h/mL, respectively). Clopidogrel is an antiplatelet drug and is commonly prescribed in the treatment of ACS, which explains the large number of patients receiving clopidogrel in the AleCardio trial. 10, 11 The effect of clopidogrel on the apparent clearance of Data are displayed as placebo-corrected absolute change from baseline with aleglitazar to month 6 (mean difference with 95% CI).
F I G U R E 3 Forest plot of safety findings of the AleCardio trial. The plot is stratified for all patients, patients using clopidogrel and patients not using clopidogrel. The forest plot shows the mean hazard ratio including the 95% confidence interval aleglitazar may be explained by the metabolism of aleglitazar, which is converted by CYP2C8 and CYP2C19 into metabolites M1 and M6. 12 Clopidogrel is an inhibitor of CYP2C8 and thus may reduce the clearance of aleglitazar. 13 Our analysis also showed that patients with high aleglitazar exposure caused by concomitant administration of clopidogrel showed an increased risk of hospitalization for heart failure, whereas patients without concomitant clopidogrel showed a trend towards a risk reduction. This finding supports the idea that a pharmacokinetic interaction between aleglitazar and clopidogrel has contributed to the increased exposure, resulting in a larger degree of sodium retention and increased risk of edema and heart failure. Nonetheless, concomitant use of clopidogrel did not explain the increased rates of gastrointestinal events and bone fractures.
Overall, body weight increased with aleglitazar compared with placebo by a mean of approximately 4 kg at 24 months. Although there may have been some contribution to increased body weight from fluid retention, the major mechanism of weight gain with PPAR-γ agonists is an increase in adipose tissue mass. 14 The phase II dose-finding trials aimed to determine the optimal dose of aleglitazar and were conducted in patients with type 2 diabetes mellitus without ACS. These studies concluded that the optimal benefit/risk balance is achieved at a daily dose of 150 μg. 16, 17 Although the population pharmacokinetic model allowed for accurate description of the pharmacokinetic variables of patients included in the pharmacokinetic substudy, the model showed some bias in the structural model and a large unexplained IIV, mainly in the apparent volume of distribution. This translated into an underprediction of the plasma concentration of aleglitazar in the higher concentration range.
As such, the presented model was less useful for simulating the pharmacokinetic profiles of the remaining 3101 patients exposed to aleglitazar, for whom no pharmacokinetic data were available. Consequently, a stratification strategy was applied for the pharmacodynamic analysis on all patients, based on the main determinants for differences in exposure to aleglitazar. As a large IIV remained unexplained in the population pharmacokinetic analysis, it cannot be excluded that we missed important covariates which also significantly contribute to the variability in exposure and response to aleglitazar. It is, therefore, 
